<DOC>
	<DOC>NCT01309698</DOC>
	<brief_summary>This study will evaluate the effect of voglibose on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.</brief_summary>
	<brief_title>Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>Diabetic patients with inadequately controlled on diet therapy and exercise therapy (HbA1c in the range 6.5 to 10.0% inclusive by NGSP) Fasting plasma glucose â‰¥ 270 mg/dL A history of Type 1 diabetes or secondary forms of diabetes Treatment of antidiabetic agents including GLP1 analogues within 8 weeks or insulin within 6 months prior to screening Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Drug interaction</keyword>
</DOC>